US Bancorp DE Sells 39,150 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

US Bancorp DE cut its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 86.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 6,223 shares of the biopharmaceutical company’s stock after selling 39,150 shares during the period. US Bancorp DE’s holdings in Catalyst Pharmaceuticals were worth $130,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in CPRX. GSA Capital Partners LLP bought a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter worth about $625,000. Victory Capital Management Inc. increased its position in Catalyst Pharmaceuticals by 5.8% in the 3rd quarter. Victory Capital Management Inc. now owns 291,505 shares of the biopharmaceutical company’s stock valued at $5,795,000 after buying an additional 15,996 shares in the last quarter. Natixis Advisors LLC increased its position in Catalyst Pharmaceuticals by 37.7% in the 3rd quarter. Natixis Advisors LLC now owns 45,637 shares of the biopharmaceutical company’s stock valued at $907,000 after buying an additional 12,491 shares in the last quarter. Quest Partners LLC increased its position in Catalyst Pharmaceuticals by 36,146.6% in the 3rd quarter. Quest Partners LLC now owns 37,334 shares of the biopharmaceutical company’s stock valued at $742,000 after buying an additional 37,231 shares in the last quarter. Finally, Segall Bryant & Hamill LLC bought a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at about $808,000. 79.22% of the stock is owned by institutional investors.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the transaction, the insider now directly owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gary Ingenito sold 44,904 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the transaction, the insider now directly owns 68,873 shares of the company’s stock, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.00% of the company’s stock.

Wall Street Analyst Weigh In

CPRX has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Robert W. Baird lifted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Stephens reiterated an “overweight” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Finally, StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $32.50.

Catalyst Pharmaceuticals Stock Up 0.7 %

Shares of NASDAQ CPRX opened at $21.02 on Monday. Catalyst Pharmaceuticals, Inc. has a twelve month low of $14.47 and a twelve month high of $24.64. The stock’s 50 day moving average price is $22.26 and its 200-day moving average price is $21.53. The company has a market capitalization of $2.55 billion, a PE ratio of 17.81, a PEG ratio of 3.31 and a beta of 0.84.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.